Sglt2 Inhibitors Have Heart Benefits For Type 2 Diabetes Patients | Latest News RSS feed

Sglt2 Inhibitors Have Heart Benefits For Type 2 Diabetes Patients - Latest News


Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

... glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in ... read more

SGLT2 inhibitors: an emerging option for cardiologists?

With studies showing potential for SGLT2 inhibitors in heart failure ... consider the class-wide impact of the cardiovascular benefits of SGLT2 inhibitors, launching a study of type 2 diabetes patient... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established ... Lower risk of heart failure and death in patients initiated on SGLT- ... read more

Looking for another news?


AstraZeneca announces CVD-REAL study of patients with T2D confirms CV benefits associated with SGLT-2 inhibitors

and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines. The results were pres... read more


Doctors have new guidelines for Type 2 diabetes

The big shift is that doctors are being told to approach their Type 2 diabetes care plan by starting with an evaluation of each diagnosed patient ... long-term heart health and blood glucose levels: s... read more

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

Adjunct to insulin The results demonstrate that when this drug, a sodium glucose cotransporter-2 inhibitor (SGLT-2 ... for use in Type 1 diabetes," he said. "We have been pioneers in conceptualizing n... read more

Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

The study is the first to report a direct comparison of SGLT2 and DPP4 inhibitors on the risk of heart failure hospitalization. People with type 2 diabetes ... patients who use other medications. “Thi... read more

ACC offers guidance on using diabetes drugs for CV event reduction

Published online Nov. 26, the paper represents a paradigm shift for how cardiovascular specialists should care for their patients with type 2 diabetes ... with heart failure or at high risk of heart f... read more

FDA approves AstraZeneca type 2 diabetes drug

Farxiga, which has already been available in Europe, belongs to a class of diabetes drugs called SGLT-2 inhibitors ... diabetes worldwide have type 2, according to the International Diabetes Federatio... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017. DOI: 10.1056/NEJMoa1611925. 9.Kosiborod M, et al. Lower risk of heart failure and de... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us